New hope for hard-to-treat colon cancer? early trial combines three drugs
NCT ID NCT07500298
First seen Apr 21, 2026 · Last updated Apr 25, 2026 · Updated 2 times
Summary
This early-phase study tests whether adding a new drug called SAR445877 to standard chemotherapy (FOLFOX6) and a targeted therapy (bevacizumab) is safe for people with a specific type of advanced colorectal cancer that hasn't spread yet. About 41 adults with microsatellite stable (MSS) metastatic colorectal cancer will take part. The main goal is to check for side effects and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.